A Homobivalent SPECT Radioligand ‐ Serinol Appended Methoxyphenyl Piperazine Derivative for Serotonin Receptor Imaging**

2021 ◽  
Vol 6 (23) ◽  
pp. 5670-5677
Author(s):  
Sandhya Rangaswamy ◽  
Meenakshi Saklani ◽  
Rajnish Kumar ◽  
Rashi Mathur ◽  
Ankur Kaul ◽  
...  
Keyword(s):  
Serotonin Receptor ◽  
Receptor Imaging ◽  
Piperazine Derivative

Synthesis and pharmacological evaluation of 11C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging

2015 ◽  
Vol 42 (4) ◽  
pp. 399-405 ◽  
Author(s):  
Svetlana V. Selivanova ◽  
Annamaria Toscano ◽  
Carmen Abate ◽  
Francesco Berardi ◽  
Adrienne Müller ◽  
...  
Keyword(s):  
Receptor Imaging ◽  
Pharmacological Evaluation ◽  
Piperazine Derivative

Preparation and biodistribution of a new 99mTc-Methoxy pheny piperazine derivative as a 5-HT1 receptor imaging agent

2011 ◽  
Vol 44 (13) ◽  
pp. S314
Author(s):  
Mostafa Erfani ◽  
Leila Hassanzadeh ◽  
Ebrahimi Seyed Esmaeil Sadat ◽  
Mohammad Mazidi
Keyword(s):  
Imaging Agent ◽  
Receptor Imaging ◽  
Piperazine Derivative

Assessment for the Role of Serotonin Receptor Subtype 3 for the Analgesic Action of Morphine at the Spinal Level

2005 ◽  
Vol 18 (2) ◽  
pp. 113
Author(s):  
Myung Ha Yoon ◽  
Hong Buem Bae ◽  
Jeong Il Choi ◽  
Seok Jae Kim ◽  
Chang Mo Kim ◽  
...  
Keyword(s):  
Serotonin Receptor ◽  
Receptor Subtype ◽  
Analgesic Action ◽  
Spinal Level ◽  
Subtype 3

Adding perphenazine to increase effectiveness of standard glioblastoma chemoirradiation. (Preprint)

2020 ◽  
Author(s):  
Richard Kast
Keyword(s):  
Dopamine Receptor ◽  
Subventricular Zone ◽  
Serotonin Receptor ◽  
Treatment Effectiveness ◽  
Short Note ◽  
Recurrent Glioblastoma ◽  
Current Standard ◽  
Medically Ill ◽  
Current Standard Treatment ◽  
Protein Phosphatase 2

UNSTRUCTURED In the effort to improve treatment effectiveness in glioblastoma, this short note reviewed collected data on the pathophysiology of glioblastoma with particular reference to intersections with the pharmacology of perphenazine. That study identified five areas of potentially beneficial intersection. Data showed seemingly 5 independent perphenazine attributes of benefit to glioblastoma treatment - i) blocking dopamine receptor 2, ii) reducing centrifugal migration of subventricular zone cells by blocking dopamine receptor 3, iii) blocking serotonin receptor 7, iv) activation of protein phosphatase 2, and v) nausea reduction. Perphenazine is fully compatible with current chemoirradiation protocols and with the commonly used ancillary medicines used in clinical practice during the course of glioblastoma. All these attributes argue for a trial of perphenazine’s addition to current standard treatment with temozolomide and irradiation. The subventricular zone seeds the brain with mutated cells that become recurrent glioblastoma after centrifugal migration. The current paper shows how perphenazine might reduce that contribution. Perphenazine is an old, generic, cheap, phenothiazine antipsychotic drug that has been in continuous clinical use worldwide since the 1950’s. Clinical experience and research data over these decades have shown perphenazine to be well-tolerated in psychiatric populations, in normals, and in non-psychiatric, medically ill populations for whom perphenazine is used to reduce nausea. For now (Summer, 2020) the nature of glioblastoma requires a polypharmacy approach until/unless a core feature and means to address it can be identified in the future. Conclusions: Perphenazine possesses a remarkable constellation of attributes that recommend its use in GB treatment.

Sign in / Sign up

Export Citation Format

Share Document